ArticleCancer reports (Hoboken, N.J.)2023

Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma.

Shuwen Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.